Patent · US Active

Aptamer-drug conjugate and use thereof

US11458120B2 · kind B2 · utility

0Cited by

0References

4Claims

0Family size

Assignee

INTEROLIGO CORPORATION · KR

Inventors

Jung Hwan Lee · Seoul, KR
Jong Hun Im · Pohang-si, KR
Jong-In Kim · Suwon-si, KR

Key dates

Filing date	Dec 4, 2017
Grant date	Oct 4, 2022
Priority date	—
Expiry date	Dec 4, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N15/115
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A cancer targeted therapeutic agent includes a drug-linker-AS1411 structure. The drug may be selected from monomethyl auristatin E (MMAE), monomethyl auristatin F (MMAF), cytarabine, gemcitabine, maytansine, DM1, DM4, calicheamicin and a derivative thereof, doxorubicin, duocarmycin and a derivative thereof, pyrrolobenzodiazepine (PBD), SN-38, a-amanitin, or a tubulysin analog.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.